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Abstract
Background
HIV-positive patients are facing age-and disease-related comorbidities. Since gender differ-
ences in viro-immunological, clinical and therapeutic features have been described, aim of
this analysis was to explore such differences in elderly HIV-positive females compared to
males coming from the same cohort.
Design
Cross-sectional study.
Setting
Ten Infectious Diseases Center participating to a new multicenter Italian geriatric Cohort
aiming at describing health transition over time in HIV-positive individuals.
Participants
HIV-positive patients aged�65 years old.
Measurements
We recorded clinical, viro-immunological and therapeutical data.
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Results
We included 210 women (17%) out of 1237 patients. Compared to males, elderly females
were less likely to present a HIV-RNA <50 copies/mL (74.3% vs. 81.8%, OR 0.64, 95%CI
0.44–0.93); they showed higher CD4+/CD8+ ratio (p = 0.016). Combined antiretroviral ther-
apy (cART) strategies were similar between genders (p>0.05), although women were less
likely to be treated with protease Inhibitors (PIs) (p = 0.05); specifically, in triple-drug regi-
mens females received less PIs (28% vs 38% p = 0.022) and more integrase inhibitors (30%
vs. 20% p = 0.012). Bone disease was more common in females (p<0.001) while males pre-
sented more frequently cardiovascular disease (CVD) (p<0.001). In females with bone dis-
ease, PIs and boosted regimens (38% vs. 53.7% p = 0.026 and 30.4 vs 44.0% p = 0.048
respectively) were prescribed less frequently. Polypharmacy was common and similar in
both genders (20% vs. 22.8%, p = >0.05). A higher use of lipid-lowering drugs (20.5% vs.
14.8%, p = 0.04) was observed in females and yet they were less likely to receive anti-
thrombotic agents (18.6% vs. 26.3%, p = 0.019) even when CVD was recorded (57.1% vs.
83.1%, p = 0.018). In multivariate analysis, we found that female gender was indepen-
dently associated with a higher CD4+/CD8+ ratio but not with virological
suppression
Conclusions
Elderly HIV-positive women display a worse virologic response despite a better immune
reconstitution compared to males. The burden of comorbidities as well as the medications
received (including cART) may slightly differ according to gender. Our data suggest that
more efforts and focused interventions are needed in this population.
Introduction
HIV epidemic has been changing dramatically in the last decades and nowadays a growing
number of people living with HIV are aged 50 years and over. According to the last estimates,
this number reaches 3.6 million people worldwide [1]. In fact, thanks to combined antiretrovi-
ral therapy (cART), HIV-positive patients experienced a reduction of mortality and a conse-
quent increase in life expectancy, which nowadays is similar to that of the general population
[2]. Moreover, due to low perception of the risk of HIV acquisition and lower awareness of
HIV disease, more people are contracting HIV in their middle and older ages [3]. Sexually
active post-menopausal women may be less likely to use condom as long as they are not wor-
ried about becoming pregnant [4]. Moreover, the physiological thinning and increased dryness
of the vaginal mucosa after menopause may expose elderly women to a higher risk of HIV
transmission [5]. Smit et al estimated that by 2030, 73% of HIV infected patients will be aged
50 years or more. Therefore, these patients will be facing HIV-related together with age-related
comorbidities [6–8], as well as the presence of several medications to treat them [9].
Even if still on debate [10,11], it has been generally accepted that geriatric age starts after 65
years old. Only few cohort studies assessed the clinical features of elderly HIV-positive per-
sons, where most of them did not focus their studies on geriatric age defined as�65 years old
and included younger patients in their studies [12–14]. To date, 51% of people living with HIV
globally are women [15] and older women accounted for the 23% of new HIV diagnosis
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among people aged 50 years or older in the United States in 2014 [4]. In a recent study from
Allavena et al, females represented around the 25% of the aging population of the French
Dat’AIDS cohort [16]. However, females keep on being less represented than males in clinical
studies [17], where very little is known about specific characteristics of elderly HIV-positive
women. Some differences in HIV infection between genders have already been pointed out in
some studies with regard to the risk of HIV acquisition [18], viro-immunological response
[19–22] and treatment choices [23], where some of these seems to be driven by socio-eco-
nomic and cultural differences between men and women, rather than by different responses to
the virus itself. Therefore, aim of this study is to explore the characteristics of elderly HIV
infected women from either a viro-immunological, clinical and therapeutic point of view in
comparison to their male counterparts, in order to better characterize this population and its
special needs for a better management of these patients in the near future.
Methods
We performed a cross-sectional, retrospective study, including HIV-positive patients aged
�65 years old. We retrieved data from the GEriatric Patients living with HIV/AIDS cOhort
(GEPPO). This is a prospective, observational, multicenter cohort including HIV-positive geri-
atric patients in follow-up by 10 HIV clinics in Italy. Main cohort inclusion criteria are: age
�65 years, confirmed HIV-positivity, being on cART for at least 6 months. Aim of this cohort
is to describe health status and transition over time in HIV-positive patients aged 65 years and
older, in order to better understand the process of aging with HIV infection. In this study, we
wanted to explore the existence of viro-immunological, clinical and/or therapeutic differences
between the female and male population. Therefore, we recorded clinical, viro-immunological
and therapeutic data at initial visit, which was performed between June 2015 and May 2016.
The following data were retrieved: age, ethnicity, HIV duration, CD4+ and CD8+ cells count,
CD4+ nadir, HIVRNA, HCVAb, HBsAg, actual cART regimen and co-medications. More-
over, we explored the presence of the following comorbidities: cardiovascular disease (CVD),
chronic kidney disease, hypertension, type 2 diabetes mellitus, bone disease, hyperlipidemia,
chronic obstructive pulmonary disease and cancer, where each condition has been previously
described in a more extensive way [24]. We defined polypharmacy as the prescription of�5
drugs not taking into account cART.
Non-parametric tests were used for all analysis. Mann-Whitney test was used for compar-
ing continuous variables among female and male participants. Categorical variables were com-
pared through Chi-square and Fisher exact tests (the latter when less than 5 participants fell
into one of the categories of the contingency tables). Two step-wise multivariate analysis were
used for estimating independent predictors of virological suppression (binary logistic regres-
sion) and CD4/CD8 ratio (linear logistic regression) including variables that showed signifi-
cant p-values at bivariate analysis. All analysis were performed through SPSS version 23.0
(SPSS, IBM Corp.).
Ethics statement
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and
the principles of Good Clinical Practice. Ethics Committee approval was obtained from
Research Ethics Board of each individual centers belonging to the GEPPO cohort. Ethics
approval was obtained by competent Ethics Committees (protocol number 0004013, reference
135/2016, Clinica Universitaria di Malattie Infettive, P.O. Amedeo di Savoia, Torino, as coor-
dinating center).
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Because this was a retrospective and non-pharmacological study, informed consent has not
been provided since in Italy ethical authorization for these studies is not needed (Italian
Guidelines for classification and conduction of observational studies, established by the Italian
Drug Agency, “Agenzia Italiana del Farmaco–AIFA” on March 20, 2008).
All data were fully anonymized before the statistical analysis was performed.
Results
We included 210 women (17%) out of 1237 patients. Overall median age was 69.8 years old
(67.1–73.9). No significant differences in HIV duration has been observed between males and
females [16.3 (10.3–21.5) vs. 15.6 (10.1–20.8), p = 0.436 in females and males respectively]
(Table 1).
Elderly HIV-positive women were less likely to present a HIV-RNA <50 copies/mL (74.3%
vs. 81.8%; OR 0.64, 95%CI 0.44–0.93; p = 0.024) while we did not find any differences in terms
of plasma HIV RNA levels between females and males with detectable (>50 copies/ml) viral
load (p = 0.559) (Fig 1). Female participants showed higher CD4+/CD8+ ratio [0.97 (0.58–
1.29) vs. 0.78 (0.53–1.16), p = 0.007] but similar current and nadir CD4+ T-cell counts. (Fig
2A, 2B and 2C). A nadir below 200 cells/mm3 was observed in 50.6% participants with no dif-
ference according to gender.
To check whether gender was independently associated the outcomes of interest we per-
formed a binary logistic regression analysis (virological suppression) and a linear regression
analysis (higher CD4/CD8 ratio) including age, current CD4+ T-cell count, nadir CD4+ t-cell
count, type of treatment, multimorbidity and polypharmacy as covariates. We found that
female gender was independently associated with a higher CD4/CD8 ratio (p = 0.003) but not
with virological suppression.
Current antiretroviral regimens were similar between the two genders (p>0.05). Triple reg-
imens were the most frequently used in both populations, being prescribed globally in about
70% of patients. Globally, women were less likely to be treated with protease inhibitors (PIs)
(39.5% vs 46.8%, p = 0.05) (Table 2). In triple-drug regimens females received less PIs (28% vs
38%, p = 0.022) and more integrase inhibitors (30% vs. 20%, p = 0.012). In females with bone
disease PIs and boosted regimens (38% vs. 53.7% p = 0.026 and 30.4 vs 44.0% p = 0.048, respec-
tively) were prescribed less frequently compared to males with bone disease.
Hyperlipidemia, hypertension and bone disease (75.3, 65.3 and 48.8%, respectively) were
the most frequent comorbidities in the female population. When the two populations were
compared, bone disease was more common in females (48.8% vs 22.9%, p<0.001) while males
presented more frequently cardiovascular disease (22.8% vs 9.5%, p<0.001).
Table 1. Characteristics of patients according to gender. Data are described as number (percentage) or median (interquartile range).
Variable Females (n = 210) Males (n = 1027) Total (N = 1237) P
Age—years 70.6 (67.3–74.8) 69.6 (67.1–73.8) 69.8 (67.1–73.9) 0.088
Caucasian ethnicity 203 (96.7%) 1013 (98.6%) 1216 (98.3%) 0.070
HIV duration—years 15.6 (10.1–20.8) 16.3 (10.4–21.5) 16.3 (10.3–21.3) 0.436
current CD4+ cell/mm3 613 (437–802) 619 (440–790) 618 (440–793) 0.606
CD4+/CD8+ ratio 0.97 (0.58–1.29) 0.78 (0.54–1.16) 0.81 (0.54–1.19) 0.007
Nadir CD4+ cell/mm3 189 (86–286) 198 (82–313) 196 (83–308) 0.484
HIV RNA <50 copies/ml 136 (74.3%) 740 (81.8%) 876 (80.5%) 0.024
HCV Ab+ 21 (10%) 104 (10.2%) 125 (10.1%) 0.956
HBsAg + 14 (6.7%) 77 (7.5%) 91 (7.3%) 0.674
https://doi.org/10.1371/journal.pone.0222225.t001
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Fig 1. Current plasma HIV RNA. Current plasma HIV RNA according to gender and stratified by:< 50 copies/mL; between 50 and 199 copies/
mL, between 200 and 999 copies/mL;>1000 copies/mL.
https://doi.org/10.1371/journal.pone.0222225.g001
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Polypharmacy was not uncommon and similarly frequent in both genders, being present in
20% of cases. A higher use of lipid-lowering drugs (20.5% vs. 14.8%, p = 0.04) was observed in
female participants. Anyway, elderly women were less likely to receive anti-thrombotic agents
(18.6% vs. 26.3%, p = 0.019) even when cardiovascular disease was recorded (57.1% vs. 83.1%,
p = 0.018). ACE inhibitors were less commonly used in female patients (27.1% vs. 33%,
p = 0.09), especially in the presence of type 2 diabetes mellitus (2.6% vs. 13.9%, p = 0.006).
Fig 2. Immunological parameters according to gender. Immunological parameters between females and males according to current CD4+T lymphocytes (panel a);
CD4+ T lymphocytes nadir (panel b); CD4+/CD8+ ratio (panel c).
https://doi.org/10.1371/journal.pone.0222225.g002
Table 2. Antiretroviral therapies, co-morbidities and polypharmacy according to gender.
Variable Females (n = 210) Males (n = 1027) Total (n = 1237) p
ARV therapies
Mono-dual 60 (28.6%) 299 (29.1%) 359 (29%)
Triple 147 (70%) 711 (69.2%) 858 (69.3%) 0.338
Other 3 (1.4%) 17 (0.3%) 20 (1.61%)
Regimen including:
PI 83 (39.5%) 481 (46.8%) 564 (45.5%) 0.05
NNRTI 86 (41%) 441 (42.9%) 527 (42.6%) 0.456
InSTI 75 (35.7%) 305 (29.7%) 380 (30.7%) 0.118
NRTI-sparing regimens 52 (24.8%) 278 (27.1%) 330(26.6%) 0.298
TDF-sparing regimens 157 (74.8%) 742 (72.2%) 899 (72.6%) 0.314
Unboosted regimens 143 (68.1%) 642 (62.5%) 785 (63.4%) 0.079
Mean comorbidities (±SD) 2.19 (±1.42) 2.37 (±1.42) 2.34 (±1.42) 0.070
Comorbidities
CVD 14 (9.5% 154 (22.8%) 168 (20.46%) <0.001
CKD 34 (21.3%) 150 (20.8%) 184 (20.8%) 0.381
Hypertension 113 (65.3%) 456 (64.5%) 569 (64.6%) 0.206
T2DM 38 (24.5%) 201 (29.1%) 239 (28.3%) 0.696
Bone disease 79 (48.8%) 134 (22.9%) 213 (28.5%) <0.001
Hyperlipidemia 134 (75.3%) 497 (70.5%) 631 (71.4%) 0.076
COPD 7 (4.8%) 57 (8.6%) 64 (7.9%) 0.191
Cancer 30 (16%) 147 (22.3%) 177 (20.92%) 0.761
Polypharmacy (�5 drug excluded cART) 42 (20%) 234 (22.8%) 254 (20.5%) 0.326
SD = standard deviation, ARV = antiretroviral, PI = Protease Inhibitors, NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitors, InSTI = Integrase Strand Transfer
Inhibitors, NRTI = Nucleos(t)ide Reverse Transcriptase Inhibitors, TDF = Tenofovir Disoproxil Fumarate, CVD = Cardiovascular Disease, CKD = Chronic Kidney
Disease, COPD = Chronic Obstructive Pulmonary Disease, cART = combination antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0222225.t002
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Discussion
To our best knowledge, this is the first study including such large sample size of geriatric
women living with HIV. Some cohort studies [12,13,25] included much lower numbers of
HIV-positive women, where geriatric age was not always defined as�65 years old.
From a virologic point of view, our results showed that women presented a lower level of
virologic suppression when compared to males (74.3% vs. 81.8%, p = 0.02).
This finding was unexpected, as long as lower viral loads has been described for women in
comparison to men in several studies, in both naïve and cART-experienced patients [23,26,27,
28]. Gender-based differences in viral load may disappear along the progression of the infec-
tion [27]. Anyway, in a cohort of naïve patients with CD4+ T cells counts <300 cell/mmc from
Grinsztejn et al [29], women showed lower values of HIVRNA also for more advanced stages
of the disease. Therefore, we hypothesized that females may have a worse virologic control
because of a lower adherence to cART as previously observed [23,30], or maybe a higher rate
of intolerance to cART drugs or a possible presence of DDis [23]. Unfortunately, the study
design did not allow to explore such factors. Moreover, as long as we tried to explore the exis-
tence of a correlation between virological replication in females and some variables such as
type of cART, comorbidities and presence of polypharmacy, no statistical significance was
found.
In our study, the nadir of CD4+ T-cell count was often <200 cell/mmc in both females and
males, which is in line with the study from Tavoschi et al [31] showing that CD4+ T-cell count
at diagnosis tends to be lower than 350 cell/mmc in older patients. Despite several studies
highlighted increased rates of HIV diagnosis in people aged 50 years or more [32–33], elderly
individuals are more likely to present late diagnosis of HIV infection [34–36]. A delay in HIV
diagnosis can be especially threatening in this population because of higher rates of mortality,
especially when an AIDS-defining event is present [37–39]. Moreover, in our analysis females
did not show a significant lower nadir of CD4+ T-cells when compared to males (189 vs 198
cell/mm3, p = 0.48, respectively). However, as long as more than 50% of our patients showed a
CD4+ T-cell count nadir <200 cell/mm3, we can hypothesize a lack of attention from both cli-
nicians and prevention strategies in this population, which may perceive a lower risk of sexu-
ally transmitted diseases in this population. Certainly, a low self-perception of the risk and a
lack of knowledge is present in older women about HIV infection and its transmission
patterns.
Nevertheless, despite worse virologic outcomes, women displayed better CD4+/CD8+ ratio
in comparison to men (1.01 vs 0.9, p = 0.016). This result was confirmed in multivariate analy-
sis, where female gender was an independent predictor of higher CD4+/CD8+ ratio.
This is in line with a recent study, which has demonstrated that female gender is a strong
predictor of immune reconstitution [40], where other studies observed the same trend in the
past years [41].
With regard to antiretroviral regimens, no differences between the two genders were found
in relation to the use of less-drug regimens. In both cases, standard triple regimens were pre-
scribed in about two thirds of patients. Anyway, we observed a slight lower prescription of PIs
in females, in both standard and less-drug regimens. In the study from Menzaghi et al [30],
women were more likely to interrupt PIs. Specifically, women on atazanavir-based regimens
were more likely to discontinue or switch treatment because of grade 1–2 adverse events, low
adherence and patient’s will, when compared to men. Moreover, in our cohort, females with
bone disease were less likely to be prescribed with PIs and boosted regimens. Pathology of
osteoporosis in HIV-positive patients is complex and has been correlated to several factors,
where its correlation with different class of drugs remained controversial [42–43]. In a
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previous study, we observed an overall increase of bone turnover in HIV-positive patients
starting cART with tenofovir/emtricitabine plus either atazanavir/ritonavir or efavirenz, where
markers of bone resorption were higher in the first group, compared to the latter [44]. On the
other hand, in a study from Yin et al, which analyzed bone loss in HIV-positive post-meno-
pausal women, the annualized rates of bone loss adjusted for baseline bone mass density
(BMD) did not differ in women on PI-based in comparison to NNRTI-based ART at any site,
while it was greater among those on treatment with tenofovir [45].
Whether our clinicians chose to prescribe less PIs in order to try to avoid metabolic effects
and eventual drug-to-drug interactions in the female population, or whether this choice was
secondary to patients adherence and/or adverse events remains uncertain, but could represent
a future matter of research.
Analyzing co-morbidities, although the mean number of co-morbidities did not differ
between the two genders, we found a significant higher prevalence of bone disease in females,
while CVD was more prevalent in males. In HIV-positive patients, regardless of age and gen-
der, bone disease is more frequent in comparison to the general population, in terms of either
presence of osteopenia/osteoporosis and/or asymptomatic vertebral fracture [46,47].
As expected, we found a higher prevalence of CVD in males. However, among people living
with HIV, CVD is frequently observed also in females and higher when compared to HIV-neg-
ative females [48]. It is important to consider that CVD is common among females overall but
often underestimated due to the fact of the challenges in atypical clinical presentation and dif-
ferential diagnosis.
Polypharmacy was present in one out of five patients, irrespectively of gender. Lipid-lower-
ing drugs were more prescribed in females compared to men. These findings showed that cli-
nicians involved in HIV care seem to pay attention to the overall risk related to hyperlipidemia
in females living with HIV, although we did not perform a specific analysis on the appropriate-
ness of prescriptions. Given that HIV per se and exposure to antiretroviral drugs have been
related to deregulations in plasmatic lipids in both males and females [48], maybe the higher
prescriptions of lipid-lowering drugs in the female population can be related to the awareness
of clinicians about metabolic changes occurring after menopause.
As our study shows, clinicians seem not to pay the same attention for what concerns CVD
in elderly females. In fact, despite previous data showed an increased risk of CV events in
HIV-positive women [49], females were less likely to receive anti-thrombotic agents even
though CVD had been present in the patient history [50,51]. In fact, there is a higher risk of
relapse of CV event potentially related to DDIs between anti-thrombotic agents and antiretro-
virals [52].
This study has some limitations: first, data of the sample of HIV-infected patients were col-
lected within the routinary clinical practice, but they were retrospectively analyzed. Therefore,
some data that could have been interesting to show and report, such as previous cART
regimes, the existence of any previous virological failures, duration of cART, pre-cART CD4
+/CD8+ ratios, were not collected. Secondly, only seven major co-morbidities were explored,
thus not allowing to draw a fully comprehensive profile of the patients we studied. Moreover,
because of the cross-sectional nature of our study is that we couldn’t study whether the higher
viremic loads in women were due to viral load blips or to virological failure.
Conclusions
This study shows that a better knowledge of this special population is necessary for the years to
come. Where some differences are already present in the management of elderly HIV-positive
women in comparison to men, some other may be further investigated and addressed.
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Especially, we believe that prevention campaigns should start to consider this population,
which is actually forgotten, in order to firstly avoid HIV-infection and secondly, to diagnose it
at earlier stages. Moreover, a better understanding of the characteristics and of the specific
needs of these population may help for a better management and retention in care for the
near, and farer, future. A gender-medicine approach should be warranted in all settings.
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